ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements with these filters
Q2 FY27 revenue INR795 cr (+40% YoY), EBITDA INR115 cr (14.4% margin), PAT INR65 cr (+117%). Management now guides ~25%+ FY27 revenue growth.
IOL Chemicals delivered strong Q2 results with significant profitability improvements, driven by non-Ibuprofen API growth and cost efficiencies, despite rising raw material prices.
Q2 FY27 standalone revenue ₹795 Cr (+40.1% YoY), EBITDA ₹114.9 Cr (14.4% margin), PAT ₹65 Cr (+116.8%). H1 revenue ₹1,551 Cr (+38.6%). Pivoting to high-value APIs with ₹495 Cr capex plan.
IOL Chemicals announced three strategic initiatives involving INR 500 Cr investment: Ibuprofen capacity expansion (to 18,000 MTPA), a new CDMO formulations facility, and a dedicated specialty chemical tolling facility.
IOL delivers a strong Q1FY27 beat driven by a 67% revenue jump in non-ibuprofen APIs and improved operating leverage.
IOLCP reported strong Q1 FY27 results with Revenue at ₹756.3 Cr (up 37.1% YoY) and PAT at ₹64.5 Cr (up 89.9% YoY). The company is strategically shifting towards high-value non-Ibuprofen APIs.
IOL reported record Q4 FY26 revenue of ₹619cr (up 17.4% YoY) and PAT of ₹53cr (up 68% YoY), driven by diversification into non-Ibuprofen APIs and improved chemical segment realization.
IOL reported strong growth in Q4 FY26 with revenue up 17.4% YoY. The company is strategically shifting towards high-value non-Ibuprofen APIs and expanding specialty chemical capacities.